Back to School: How biopharma can reboot drug development. Access exclusive analysis here
AstraZeneca (AZN; LSE:AZN) posted second quarter EPS of $0.45, a 15% increase over the $0.39 posted in
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury